ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

20.17 +0.43 (+2.18%)

Delayed Quote Updated: 4:00 PM EDT, Oct 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

19 20 Next >

Acadia Pharmaceuticals Announces Planned Retirement of President Srdjan (Serge) Stankovic

October 27, 2022

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022

October 20, 2022

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals Appoints Adora Ndu, Pharm.D., J.D. to its Board of Directors

October 13, 2022

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals Recognizes Rett Syndrome Awareness Month and Launches New Awareness Campaign, Rett Revealed

October 04, 2022

From Acadia Pharmaceuticals

Via Business Wire

FDA Asks For Additional Study For Acadia's Pimavanserin In Alzheimer's-Associated Delusions ↗

August 05, 2022

Via Benzinga

Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary ↗

September 12, 2022

Via Benzinga

U.S. FDA Accepts Acadia's Filing For Rett Syndrome Candidate Under Priority Review ↗

September 12, 2022

The U.S. Food and Drug Administration (FDA) has accepted for filing Acadia Pharmaceuticals’ (NASDAQ: ACAD) New Drug Application (NDA) of trofinetide for the treatment of Rett syndrome. The regulatory...

Via Benzinga

Acadia Pharmaceuticals Announces Trofinetide New Drug Application for the Treatment of Rett Syndrome has been Accepted for Filing and Review by U.S. FDA

September 12, 2022

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals to Present at Upcoming Investor Conferences

September 01, 2022

From Acadia Pharmaceuticals Inc.

Via Business Wire

Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know ↗

August 31, 2022

After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.

Via Benzinga

ACADIA Pharmaceuticals's Return On Capital Employed Insights ↗

August 29, 2022

According to Benzinga Pro data, during Q2, ACADIA Pharmaceuticals (NASDAQ:ACAD) posted sales of $134.56 million. Earnings were up 69.92%, but ACADIA Pharmaceuticals still reported an overall loss of...

Via Benzinga

Acadia Terminates Painkiller, Cancer Candidate After Disappointing Data ↗

August 09, 2022

Via Benzinga

ACADIA Pharmaceuticals Faces Several Price Target Cuts After Q2 Results, But This Analyst Disagrees ↗

August 09, 2022

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) reported upbeat results for its second quarter after the closing bell on Monday.

Via Benzinga

NVIDIA To $240? Here Are 5 Other Price Target Changes For Tuesday ↗

August 09, 2022

Raymond James cut the price target on NVIDIA Corporation (NASDAQ: NVDA) from $250 to $240. Raymond James analyst Melissa Fairbanks maintained the stock with a Strong Buy. NVIDIA shares fell 2.8% to...

Via Benzinga

ACADIA Pharmaceuticals: Q2 Earnings Insights ↗

August 08, 2022

ACADIA Pharmaceuticals (NASDAQ:ACAD) reported its Q2 earnings results on Monday, August 8, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Via Benzinga

Acadia Pharmaceuticals Reports Second Quarter 2022 Financial Results

August 08, 2022

From Acadia Pharmaceuticals Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022 ↗

August 08, 2022

Via Benzinga

8 Analysts Have This to Say About ACADIA Pharmaceuticals ↗

August 05, 2022

Analysts have provided the following ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) within the last quarter:

Via Benzinga

Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases ↗

August 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Benzinga Before The Bell: Should Investors Worry About Tesla's China Sales, Gold Back In Focus, Nio Smartphone Could Soon Be A Reality Other Top Financial Stories Friday, August 5 ↗

August 05, 2022

CNBC International Airlines Prepare For Mayhem Of Summer Travel Season: Report

Via Benzinga

Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis

August 04, 2022

From Acadia Pharmaceuticals Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022 ↗

August 05, 2022

Upgrades

Via Benzinga

Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate ↗

August 04, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Biotech Investors: August's Key PDUFA Catalysts You Must Know ↗

July 31, 2022

Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the...

Via Benzinga

Acadia Pharmaceuticals to Announce Second Quarter 2022 Financial Results on August 8, 2022

July 25, 2022

From Acadia Pharmaceuticals Inc.

Via Business Wire

The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings ↗

July 19, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Recap of Monday's Biotech Catalysts - End of the Day Summary ↗

July 18, 2022

Abbvie (NYSE: ABBV) has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least...

Via Benzinga

Acadia Seeks FDA Approval For Genetic Neurological Disorder Candidate ↗

July 18, 2022

Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for trofinetide for the treatment of Rett syndrome.

Via Benzinga

Acadia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Trofinetide for the Treatment of Rett Syndrome

July 18, 2022

From Acadia Pharmaceuticals Inc.

Via Business Wire

Where ACADIA Pharmaceuticals Stands With Analysts ↗

July 11, 2022

Analysts have provided the following ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) within the last quarter:

Via Benzinga

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.